References
- FarielloRGSafinamideNeurotherapeutics2007411011617199024
- ChazotPLSafinamide (Newron Pharmaceuticals)Curr Opin Investig Drugs20012809813
- MoussaBHBakhleYBakhleYSMonoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illnessBr J Pharmacol2006147S287S29616402116
- YoudimMGrossAFinbergJRasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBr J Pharmacol200113250050611159700
- MahmoodIClinical pharmacokinetics and pharmacodynamics of selegiline. An updateClin Pharmacokinet1997332911029260033
- CacciaCMajRCalabresiMSafinamide: from molecular targets to a new anti-Parkinson drugNeurology200667S18S2317030736
- MarzoADal BoLCeppi MontiNPharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activityPharmacol Res200450778515082032
- CattaneoCCacciaCMarzoAMajRFarielloRGPressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibitionClin Neuro Pharmacol200326213217
- MarquetAKupasKJohneAThe effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trialClin Pharmacol Ther201292445045722948897
- StocchiFArnoldGOnofrjMImprovement in motor function in early Parkinson disease by safinamideNeurology20046374674815326260
- StocchiFVaccaLGrassiniPSymptoms relief in Parkinson’s disease by safinamide. Biochemical and clinical evidence beyond MAO-B inhibitionNeurology200667S24S2917030737
- StocchiFBorgohainROnofrjMStudy 015 InvestigatorsA randomized, double-blind, placebo controlled trial of safinamide as add on therapy in early Parkinson’s disease patientsMov Disord20122710611221913224
- ElghEDomellöfMLinderJEdströmMStenlundHForsgrenLCognitive function in early Parkinson’s disease: a population-based studyEur J Neurol2009161278128419538208
- VerbaanDMarinusJVisserMCognitive impairment in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry2007781182118717442759
- SharmaTAnandRStocchiFBorgohainRRossettiR015 Study GroupCognitive effects of Safinamide in early Parkinson’s disease patientsInternational Congress of Parkinson’s Disease and Movement DisordersJune 3–7, 2007Istanbul, Turkey
- SchapiraAHVStocchiFBorgohainRStudy 017 InvestigatorsLong-term efficacy and safety of safinamide as add-on therapy in early Parkinson’ diseaseEur J Neurol20132027128022967035
- BaronePFernandezHFerreiraJJSafinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease patients (MOTION Study)65th Annual Meeting of the American Academy of Neurology (AAN)March 16–23, 2013San Diego Convention Center, San Diego, CA, USA
- Clinical Study Report Newron Pharmaceutical S.p.A, Zambon S.p.A. Safinamide Protocol n. 2791810252013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002396/WC500184967.pdf
- BorgohainRSzaszJStanzionePStudy 016 InvestigatorsRandomized trial of safinamide add-on to Levodopa in Parkinson’s disease with motor fluctuationsMov Disord201429222923724323641
- BorgohainRSzaszJStanzionePStudy 018 InvestigatorsTwo year, randomized, controlled study of Safinamide as add-on to levodopa in mid to late Parkinson’s diseaseMov Disord201429101273128025044402
- CattaneoCLa FerlaRBonizzoniELong-term effects of safinamide on dyskinesia in mid-to late-stage Parkinson’s disease: a post-hoc analysisJ Parkinsons Dis2015547548126406127
- SchapiraAFoxSHauserRSafinamide add on to l-dopa: at randomized, placebo controlled 24 weeks global trial in patients with Parkinson’s disease and motor fluctuations65th Annual Meeting of the American Academy of Neurology (AAN)March 16–23, 2013San Diego Convention Center, San Diego, CA, USA
- BlandiniFAn update on the potential role of excitotoxicity in the pathogenesis of Parkinson diseaseFunct Neurol201025657120923603
- ChapuisSOuchchaneLMetzOImpact of the motor complications of Parkinson’s disease on the quality of lifeMov Disord20052022423015384126
- GregoireLRoachADi PaoloTSafinamide reduces levodopa-induced dyskinesias in MPTP-lesioned primates while prolonging anti-parkinsonian efficacyMov Disord201025suppl 2S308
- Verhagen MetmanLDel DottoPBlanchetPJvan den MunckhofPChaseTNBlockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s diseaseAmino Acids1998141475829871445
- AnandROnofrjMSchapiraAHSafinamide potentiates the effects of DA-agonists in early stage Parkinson’s disease (PD) patientsMov Disord20072216S99